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Facts
=====

p53 causes cell cycle arrestp21/CDKN1A is required for indirect transcriptional repression by p53The DREAM protein complex is a transcriptional repressorCHR and E2F promoter elements bind the DREAM complexp21/CDKN1A initiates a switch from activating B-MYB- and FOXM1-containing complexes to the repressing DREAM complexp53 indirectly downregulates many cell cycle genes

Open Questions
==============

How do p63, p73 and p53 variants influence the p21--DREAM--E2F/CHR (p53--DREAM) pathway?Are cellular kinase inhibitors other than p21/CDKN1A regulating this pathway?Which clinical benefits can be achieved in cancer treatment with small-molecule CDK inhibitors by compensating for defects in the p53--DREAM pathway?What are the overlaps or differences in pRB and DREAM function?

Prologue
========

One central role of the tumor suppressor p53 is to arrest the cell cycle. p53 indirectly downregulates the expression of many genes which are essential for progression through the cell division cycle. The detailed mechanism of indirect transcriptional repression by p53 has only recently become clear. p53 employs a protein complex named DREAM to downregulate gene expression. DREAM functions as a transcriptional repressor complex. With the advent of genome-wide experimental and bioinformatic analyses, we are now in the position to assess the wide spectrum of genes controlled through the newly defined p53--DREAM pathway.

p53 Downregulates Expression of Cell Cycle Genes
================================================

p53 is at the heart of several fundamental cellular signaling pathways.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ The most important of these pathways for p53's tumor-suppressive role are induction of apoptosis and cell cycle arrest.^[@bib5],\ [@bib6]^

Cell cycle arrest can be achieved by depleting regulatory proteins required for cell cycle progression. Upon p53 activation, genes for many central cell cycle proteins are transcriptionally downregulated. Key examples for genes repressed after induction of p53 are *cyclin A*,^[@bib7]^ polo-like kinase 1 (*PLK1*),^[@bib7]^ *cyclin B1*,^[@bib8],\ [@bib9],\ [@bib10]^ *cyclin B2*,^[@bib10]^ cyclin-dependent kinase 1 (*CDK1*),^[@bib11]^ *CDC20*,^[@bib12]^ cell cycle phosphatases *CDC25A*^[@bib13]^ and *CDC25C*,^[@bib14]^ DNA replication licensing factor *MCM5*,^[@bib7],\ [@bib15]^ *CKS1*^[@bib16]^ and antiapoptotic *Survivin* (*BIRC5*).^[@bib7]^ Even such a small selection of genes exemplifies that p53-dependent downregulation of expression affects many aspects of cell cycle regulation.

Transcriptional Repression by p53 is Indirect
=============================================

Transcriptional regulation is essential to the function of p53 as a tumor suppressor.^[@bib2]^ Interestingly, the number of genes downregulated after p53 activation (approximately 2700) is larger than the number of genes activated by p53 (approximately 2200).^[@bib17]^ Before this enigma was finally solved, several mechanisms had been proposed to explain how p53 can serve as a transcriptional activator as well as a repressor.^[@bib2],\ [@bib4],\ [@bib18]^ However, experimental data obtained for particular genes were often not consistent with the suggested mechanism or results published for certain genes by different groups were contradictory.^[@bib17],\ [@bib18],\ [@bib19]^ Furthermore, different models for p53-dependent repression require direct binding of p53 to the downregulated gene. However, genome-wide mRNA expression and chromatin immunoprecipitation (ChIP) results demonstrated that this requirement is not fulfilled for most repressed genes. Only about 3% of the genes downregulated by p53 are also bound by p53.^[@bib17]^ Thus, essentially all genes are downregulated by p53 indirectly.

Prior to the availability of genome-wide ChIP data on binding of p53 and other factors potentially involved in transcriptional repression, it was not evident by which mechanism p53 downregulates a plethora of cell cycle genes. This changed when the mammalian DREAM complex together with its target genes was discovered^[@bib20],\ [@bib21]^ and the observation was made that DREAM is formed following p53 induction.^[@bib22]^

DREAM is a Transcriptional Repressor
====================================

The DREAM transcriptional complex displays two remarkable features. It changes its composition to exert opposing functions in gene regulation and it contains two subunits that bind to distinct DNA elements.

DREAM is composed of the MuvB core complex, E2F4-5/DP, and p130 or p107 proteins, which are related to the retinoblastoma tumor suppressor pRB^[@bib20],\ [@bib21]^ ([Figure 1](#fig1){ref-type="fig"}). E2F4, E2F5 and p130/p107 had long been implicated in transcriptional repression via E2F sites.^[@bib23]^ Consistently, DREAM was initially identified as a complex which binds promoters through E2F sites.^[@bib20],\ [@bib21],\ [@bib24]^ However, DREAM loses its E2F/pRB-related components to associate with the transcriptional activators B-MYB and FOXM1 during the cell cycle.^[@bib20],\ [@bib22],\ [@bib25],\ [@bib26],\ [@bib27]^ Thus, these MuvB-based complexes cannot bind E2F sites. DREAM as all other MuvB-derived complexes binds DNA through cell cycle genes homology regions (CHRs).^[@bib28],\ [@bib29],\ [@bib30]^ CHR transcriptional elements are distinct from E2F sites and are bound by the LIN54 component of MuvB^[@bib31],\ [@bib32]^ ([Figure 1](#fig1){ref-type="fig"}).

MuvB-based complexes can switch their function. Association of MuvB with B-MYB or FOXM1 switches DREAM to B-MYB-MuvB (MMB), FOXM1-MMB or FOXM1-MuvB complexes and turns the MuvB core from repressor to activator. This change in protein composition of MuvB-based complexes is connected to progression through the cell cycle and explains the switch from repression to activation via the same DNA site in the target promoters, that is, the CHR element ([Figure 1](#fig1){ref-type="fig"}).

It has been discussed whether B-MYB and FOXM1 require additional direct DNA binding when they are in a complex with MuvB.^[@bib19],\ [@bib26],\ [@bib29],\ [@bib31],\ [@bib33],\ [@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^ Generally, MYB consensus sites or forkhead binding sites are not observed close to the MuvB-binding CHR elements. For FOXM1 it was reported that it mostly binds to non-forkhead binding sites in the genome and that this nonspecific DNA binding may support association of MuvB with DNA.^[@bib35],\ [@bib36]^ Possibly, also B-MYB binds to sites far from CHR elements to augment MMB-LIN54 binding to DNA.

Recently, the importance of CHR sites in cancer signaling pathways yet again has been demonstrated when the computer software SWItchMiner (SWIM) was employed to search for crucial nodes in signaling networks -- called switch genes -- out of a large panel of cancer data sets from The Cancer Genome Atlas.^[@bib38]^ The analysis yielded 100 significant switch genes which are mostly upregulated in a panel of different tumor types. With this selection of genes a *de novo* motif search for promoter elements was carried out. Interestingly, the CHR element emerged as a crucial site central to the regulation of the switch genes from the cancer signaling nodes.^[@bib38]^

In addition to binding to single E2F or CHR sites, DREAM binding can be supported by two other elements, CDE (cell cycle-dependent element) and CLE (CHR-like element) sites ([Figure 2](#fig2){ref-type="fig"}). CLE sites are weak CHR-like elements and augment binding of DREAM to E2F sites. In general, affinity of CLE sites toward MuvB-based complexes, also the activating complexes, is not sufficient for binding. CLE sites alone cannot bind DREAM and an E2F element is required in tandem. Also, promoters require a spacer of four nucleotides between E2F and CLE sites.^[@bib33]^ Similarly, CDE sites support binding of DREAM only when a CHR element is present in the promoter. Again, a spacer of four bases is found between CDE and CHR sites.^[@bib33]^ CHR and CLE sites are contacted by LIN54 of the MuvB core complex.^[@bib28],\ [@bib32]^ Thus, DREAM binds to promoter DNA by four different modes^[@bib33]^ ([Figure 2](#fig2){ref-type="fig"}).

The p53--p21--DREAM--E2F/CHR Pathway
====================================

After the discovery of DREAM binding to E2F and CHR elements, the pathway by which p53 downregulates many genes became evident.^[@bib39]^ In short, this pathway requires transcriptional upregulation of *p21/CDKN1A*. p21/CDKN1A inhibits cyclin-dependent kinases (CDKs) which phosphorylate the pRB-related proteins p107 and p130. Thus, p21/CDKN1A expression results in hypophosphorylation of p107 and p130. In this hypophosphorylated state, p107 and p130 can join other proteins to form the DREAM complex and thereby repress transcription through DREAM binding to E2F or CHR promoter sites ([Figure 3](#fig3){ref-type="fig"}).

The CDK inhibitor *p21/CDKN1A* (WAF1, CIP1) was the first transcriptional target identified for p53.^[@bib40],\ [@bib41]^ And with this target the more detailed description of the pathway starts. Upon p53 activation, *p21/CDKN1A* is transcriptionally upregulated through direct binding of p53 to sites in the *p21/CDKN1A* promoter ([Figure 3](#fig3){ref-type="fig"}).^[@bib39]^

One question that still needs to be addressed systemically is how the p53-related p63 and p73 protein families influence transcription of *p21/CDKN1A.* Especially the TAp63/TAp73 variants have similar functions in regulating gene transcription as p53.^[@bib42],\ [@bib43]^ The DNA binding motifs for p63, p73 and p53 are apparently essentially identical,^[@bib44],\ [@bib45],\ [@bib46],\ [@bib47]^ suggesting that the transcriptionally active members of the p63 and p73 families may contribute to cell cycle arrest through activating *p21/CDKN1A.*^[@bib43],\ [@bib48],\ [@bib49]^ However, early experiments with overexpression of p63 and p73 variants indicated a reduced ability to induce *p21/CDKN1A* expression compared with p53 and showed only minor effects on genes which are downregulated by p53.^[@bib13],\ [@bib16],\ [@bib48],\ [@bib50],\ [@bib51]^

Another challenge in delineating activation of *p21/CDKN1A* is the formation of hetero-tetramers between p53 isoforms and the various proteins of the p53/p63/p73 family.^[@bib52],\ [@bib53]^ In particular, tetramer formation including isoforms such as Δ40p53 and Δ133p53 may compromise activation of *p21/CDKN1A* by other p53 family members.^[@bib43]^ Which combination of p53 isoforms and other p53/p63/p73 family members compete for binding sites in the *p21/CDKN1A* promoter depends on cell type and developmental stage-specific expression of these factors.

As the next step in the p53--DREAM pathway, p21/CDKN1A inhibits cyclin-dependent kinase complexes such as cyclin E/A-CDK2 and cyclin D-CDK4/6.^[@bib54],\ [@bib55]^ In turn, these cyclin/CDK complexes are no longer able to phosphorylate p107 and p130.^[@bib56]^ The resulting hypophosphorylated p107 or p130 proteins attach to the MuvB core complex and shift the equilibrium from FOXM1-MMB to DREAM.^[@bib22],\ [@bib35],\ [@bib39]^ Concomitant to this shift in MuvB-derived complex composition, transcriptional activation through FOXM1-MMB switches to repression by DREAM. Thus, genes active before p53 activation become repressed following p53 induction ([Figure 3](#fig3){ref-type="fig"}). At this step, the DREAM pathway shows a parallel regulation to the control by pRB because hypophosphorylation of pRB leads to pRB/E2F complex formation.^[@bib57]^

p21/CDKN1A is most likely not the only protein which can inhibit cyclin/CDK complexes that can phosphorylate p107 and p130, thereby promoting DREAM formation.^[@bib56]^ Other CDK inhibitor proteins can substitute for p21/CDKN1A to inhibit cyclin E/A-CDK2 and cyclin D-CDK4/6 combinations.

These inhibitors include p27/Kip1/CDKN1B and p57/Kip2/CDKN1C, both members of the Cip/Kip family with broad complex formation capacity, as well as p16/INK4A/CDKN2A, p15/INK4B/CDKN2B, p18/INK4C/CDKN2C and p19/INK4D/CDKN2D of the INK4 family with narrow binding specificity towards cyclin D-CDK4/6 complexes.^[@bib58]^

Although the function of p21/CDKN1A in cell cycle checkpoint control and thus a possible role in tumor suppression has been confirmed many times, one observation that may be related to this possible cdk inhibitor redundancy is the absence of p21/CDKN1A mutations in tumors and the lack of spontaneous tumorigenesis in *p21/Cdkn1a* (−/−) mice.^[@bib59],\ [@bib60]^ Consistently, recent results from several knockout models show that loss of p21/CDKN1A function alone is not sufficient for tumor development.^[@bib61],\ [@bib62]^

Cyclin-dependent kinase regulation may even be more complex. Contrasting the canonical CDK inhibitor function, potential activation of cyclin/CDK complexes by p21/CDKN1A and p27/Kip1/CDKN1B has been discussed, with CDK inhibitors functioning as cyclin/CDK assembly factors, mediating nuclear localization of D-type cyclins, and contributing to stability of cyclin D-CDK4 complexes.^[@bib58],\ [@bib63],\ [@bib64]^ Thus, it remains open whether additional signaling steps aside from the p53--p21/CDKN1A axis signal into the DREAM pathway.

Target gene selection by DREAM dictates the cellular response of indirect p53-mediated gene repression. Four types of binding represented by the two main classes of target genes with either E2F or CHR sites can be distinguished ([Figure 2](#fig2){ref-type="fig"}). Depending on the specific promoter of the gene, either E2F or CHR elements bind the complexes independently or with the support of CDE or CLE sites, respectively ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Before the p53-dependent switch to transcriptional repression, target genes are activated by two different mechanisms. E2F elements bind E2F1-3/DP proteins for activation, whereas promoters carrying CHR sites are activated by FOXM1-MMB. Both groups of promoter elements then switch to DREAM binding for repression ([Figure 3](#fig3){ref-type="fig"}).

Taken together, this sequence of reactions constitutes the p53--p21--DREAM--E2F/CHR or short the p53--DREAM pathway.^[@bib39]^

Target Genes for Indirect p53-Dependent Repression
==================================================

With the p53--DREAM pathway as a basis, criteria for identification of targets for indirect transcriptional downregulation by p53 are straightforward to define. Downregulation of target mRNA following p53 activation, DREAM binding to the target gene, and the presence of E2F or CHR sites in the proximal promoter are pivotal criteria for identification of target genes. There are many studies describing changes in mRNA levels employing a few different cell systems to compare expression with or without active p53.^[@bib17],\ [@bib65]^ Furthermore, the binding of DREAM components to these target genes can be assayed by ChIP. Subsequently, this information can be combined with the presence of E2F or CHR sites in the promoters. Of course, the quality of p53--DREAM target identification improves considerably the more results from independent studies are combined. We have employed bioinformatic tools to search for overlaps in a large number of reports on differential mRNA expression after p53 induction, on the binding of DREAM components by ChIP, and whether the potential target genes display E2F or CHR elements.^[@bib17],\ [@bib66]^ With a more recent analysis, the [www.targetgenereg.org](http://www.targetgenereg.org) website was established. This site is updated with links to new data reports and allows retrieving results from genome-wide analyses easily.^[@bib65],\ [@bib67]^

Here, a compilation of p53--DREAM target genes is provided ([Table 1](#tbl1){ref-type="table"}). In order to obtain a catalog of high-confidence targets, criteria for inclusion as targets were binding of p130, E2F4, LIN9, LIN54, and the lack of binding by p53 as assayed by ChIP in combination with downregulation of target gene mRNA after activation of p53. The data for individual genes were retrieved from [www.targetgenereg.org](http://www.targetgenereg.org) and several meta-analyses.^[@bib17],\ [@bib29],\ [@bib31],\ [@bib65],\ [@bib66],\ [@bib67]^ Although most of the p53--DREAM target genes were identified merely by such meta-analyses, several genes such as *CCNB1, CDK1, CCNB2, KIF23, PLK4, BIRC5, CDC25C* and *PLK1* have already been found or confirmed in detailed experiments as targets of the p53--DREAM pathway.^[@bib19],\ [@bib22],\ [@bib39],\ [@bib68],\ [@bib69]^ Nevertheless, meta-analyses of genome-wide studies bypass such experimental efforts for individual genes and yield more than 250 high-confidence p53--DREAM targets ([Table 1](#tbl1){ref-type="table"}).

The compilation of p53--DREAM targets represents numerous cellular functions ([Table 1](#tbl1){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}). The many protein classes found among the p53--DREAM targets are illustrated by examples such as kinases, protein chaperones, DNA helicases, ubiquitin ligases, phosphatases, methyltransferases, nucleases, ATPases and transcription factors ([Table 1](#tbl1){ref-type="table"}). Most gene products participate in cell cycle control. Examples for particular functions are DNA replication, nucleosome packaging, mitotic spindle assembly and chromosome segregation. Thus, it is becoming evident that the p53--DREAM pathway coordinately downregulates a plethora of genes which are categorized into functional groups ([Figure 4](#fig4){ref-type="fig"}).

Checkpoint Control from DNA Synthesis to Cytokinesis
====================================================

p53 can induce cell cycle arrest at several stages, including G~1~/S and G~2~/M checkpoints.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ For example, it has been shown that p53 can induce G~1~ arrest via p21/CDKN1A-dependent inhibition of cyclin A/E-CDK2.^[@bib55]^ Also progression through G~2~ phase and mitosis can be affected by p53, as several early studies showed that p53 is responsible for the downregulation of many genes important for checkpoint control from G~1~ through cytokinesis.^[@bib70],\ [@bib71],\ [@bib72],\ [@bib73]^ However, at the time it was not evident that such checkpoint control by p53 is based on a common mechanism^[@bib17],\ [@bib39],\ [@bib66]^ ([Figure 3](#fig3){ref-type="fig"}). Now it is apparent that many proteins controlling cell cycle checkpoints are regulated by the p53--DREAM pathway and are clustered in functional groups ([Table 1](#tbl1){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}).

Coordinated Transcriptional Repression by the p53--DREAM Pathway
================================================================

A major feature of p53-dependent repression is that whole groups of functionally related genes are indirectly downregulated. Many such groups are defined by their function and timing of expression during the cell cycle. DREAM-dependent transcriptional repression employs binding to E2F or CHR sites as a determinant for early or late expression in the cell cycle, respectively.^[@bib31],\ [@bib33]^ Genes with maximum expression in the G~1~ and S phases are controlled through E2F or E2F/CLE sites and can be activated by E2F1-3/DP complexes, whereas genes expressed in the G~2~ phase and mitosis are upregulated by MMB and FOXM1-MuvB activator complexes through CHR or CDE/CHR elements ([Figure 1](#fig1){ref-type="fig"}).

G~1~/S Checkpoint Genes are Repressed by DREAM Binding to E2F Sites
===================================================================

One group of DREAM target genes important for the G~1~/S checkpoint is represented by *POLA1, MCM2* and *ORC1*^[@bib74],\ [@bib75]^ ([Table 1](#tbl1){ref-type="table"}). Furthermore, several DREAM targets, that is, *cyclin A, CDK2, CDC6* and *CDT1,* are active in a checkpoint preventing rereplication ([Table 1](#tbl1){ref-type="table"}).^[@bib73],\ [@bib76]^ Interestingly, many genes previously described as classical E2F targets and hallmark genes for S phase progression such as *TK1* and *DHFR* are now considered p53--DREAM targets^[@bib77],\ [@bib78]^ ([Table 1](#tbl1){ref-type="table"}). The E2F or E2F/CLE sites in their promoters are bound by DREAM for repression in resting cells and the E2F elements may bind activating E2F complexes at later stages of the cell cycle^[@bib33]^ ([Figure 1](#fig1){ref-type="fig"}).

p53-Repressed Genes Required for the G~2~ Phase and Mitosis are Controlled by CHR Elements
==========================================================================================

In addition to controlling the G~1~/S checkpoint, p53 also has a role in regulating genes required for progression through G~2~ phase and mitosis.^[@bib30],\ [@bib66],\ [@bib79]^ Cell cycle-dependent expression of these genes is controlled by CHR or CDE/CHR sites in their promoters^[@bib31],\ [@bib33]^ ([Figure 1](#fig1){ref-type="fig"}). Prominent examples for p53--DREAM-regulated genes involved in G~2~/M checkpoint control and progression through mitosis are *CHEK2, CDK1, CCNB1, CCNB2* and *CDC25C*^[@bib10],\ [@bib14],\ [@bib31],\ [@bib39],\ [@bib66],\ [@bib80],\ [@bib81]^ ([Table 1](#tbl1){ref-type="table"}).

In addition to such central regulators, also genes coding for proteins required in the mechanical execution of mitosis are controlled by the p53--DREAM pathway, such as kinesins.^[@bib82]^ Of the many kinesins discovered in bioinformatic screens as p53--DREAM targets, *KIF2C, KIF23* and *KIF24* have been studied in detail and were validated to be controlled by DREAM^[@bib29],\ [@bib31],\ [@bib68],\ [@bib83]^ ([Table 1](#tbl1){ref-type="table"}).

The p53--DREAM Pathway and its Role in the Spindle Assembly Checkpoint, Chromosomal Instability, Aneuploidy in Cancer Cells and Mitotic Catastrophe
===================================================================================================================================================

Several gene products mentioned above together with many additional cell cycle proteins are required for accurate segregation of chromosomes. Deregulation of their genes can perturb the spindle assembly checkpoint and lead to chromosomal instability (CIN).^[@bib84],\ [@bib85],\ [@bib86],\ [@bib87]^ CIN and resulting aneuploidy are considered hallmarks of cancer cells. Deregulated expression of mitosis genes has been shown in numerous studies to cause aneuploidy and tumor development.^[@bib88]^ Importantly, many genes involved in chromosome segregation are p53--DREAM targets ([Table 1](#tbl1){ref-type="table"}). Similarly, several genes important for mitosis which are downregulated by the p53--DREAM pathway are part of the DNA damage response. Repression of these genes leads to perturbations in the mitotic machinery. As a consequence of depriving cells of these regulators, cells can arrest in mitosis and undergo the death program of mitotic catastrophe.^[@bib89]^

As chromosomal missegregation causes elevated levels of p53 and p21/CDKN1A,^[@bib90]^ the p53--DREAM pathway becomes activated and many genes required for segregation of chromosomes are downregulated ([Table 1](#tbl1){ref-type="table"}). The lack of expression of segregation regulators results in cell cycle arrest. In cells that have lost p53 or p21/CDKN1A function, the ability to arrest the cell cycle is compromised causing CIN and aneuploidy.^[@bib90]^

Numerous gene products involved in mitotic spindle formation, kinetochore function, microtubule binding, centromere organization and centrosome formation such as CENP-A/C/E/F/L/N/O/W, CAF1A, MCM2-8, INCENP and CEP152/295 are implicated as p53--DREAM targets ([Table 1](#tbl1){ref-type="table"}). Furthermore, several genes involved in these processes -- *BIRC5* (Survivin), *CEP55*, *PLK1, GAS2L3* and *PRC1 --* have been established as DREAM targets in detailed experimental studies.^[@bib19],\ [@bib91],\ [@bib92],\ [@bib93]^

As two examples, the histone H3-like CENP-A protein (CenH3) and its chaperone HJURP (Holliday junction recognition protein) have important functions in centromere formation. Their expression peaks in the G~2~ phase. CENP-A is incorporated into centromeric chromatin between telophase and early G~1~ to form centromere-specific nucleosomes and to facilitate kinetochore binding to the centromere.^[@bib94]^ *CENPA* and *HJURP* genes had been predicted as targets repressed by the p53--DREAM pathway.^[@bib66]^ Recently, it has been confirmed that these two factors are indeed downregulated indirectly by p53 requiring CDE/CHR sites in their promoters and a functional p21/CDKN1A CDK inhibitor.^[@bib95]^ Consistently, expression of *CENPA* and *HJURP* mRNA was found increased in several tumor types which lack functional p53 compared with samples with wild-type p53. Notably, the report suggests that overexpression of *CENPA* and *HJURP* is not simply a consequence but may be one of the causes of cell cycle deregulation after p53 inactivation and cellular transformation. This assumption stems from the observation that mRNA levels of the G~2~/M genes *CENPA* and *HJURP* remain high even when a decreasing proportion of cells enters G~2~/M and an increasing proportion of cells undergoes apoptosis.^[@bib95]^

Also in the context of preventing supernumerary centrosomes, the formation of the PIDDosome from its components together with its regulatory effect on p53 displays a balancing network of feedback loops. The PIDDosome via Caspase-2 mediates MDM2 cleavage leading to p53 stabilization and p21/CDKN1A activation.^[@bib96]^ While expression of the PIDDosome constituent *PIDD1* is strongly induced, expression of another component, *CRADD* (*RAIDD*), is not significantly affected by p53.^[@bib17]^ In contrast, the *CASP2* (Caspase-2) component is clearly downregulated, possibly via p53--DREAM.^[@bib17]^

Furthermore, it has been shown that loss of p53 causes centrosome amplification.^[@bib97]^ Particularly overexpression of cell cycle regulators such as PLK4, which is also downregulated by the p53--DREAM pathway, was reported to be central to the amplification of centrosomes.^[@bib69],\ [@bib98]^ More importantly, overexpression of these genes was implicated not as a consequence but rather as a cause contributing to the formation of tumors^[@bib92],\ [@bib98]^

As a result, deregulation of p53 cell cycle targets leads to centrosome amplification which promotes aneuploidy and ultimately tumorigenesis.^[@bib98]^ In general, these observations suggest a tumor-suppressive function of the p53--DREAM pathway.

Entire functional Groups of Genes are Downregulated by the p53--DREAM Pathway: DNA Repair, Telomere Maintenance and Fanconi Anemia
==================================================================================================================================

Bioinformatic analysis of mRNA expression, ChIP and promoter element conservation data pointed at several genes involved in DNA repair and telomere maintenance to be downregulated by the DREAM pathway.^[@bib17]^ Among the genes suggested to be regulated by DREAM were examples such as *FANCB*, *DCLRE1B* (*Apollo*), *RAD54L*, *RAD18* and *CHEK2*^[@bib17],\ [@bib31],\ [@bib66]^ ([Table 1](#tbl1){ref-type="table"}). Interestingly, some of the DREAM targets are genes of the Fanconi anemia complementation groups ([Table 2](#tbl2){ref-type="table"}).^[@bib17],\ [@bib99]^

Fanconi anemia is the most common inherited bone marrow failure syndrome. It causes constitutive genomic instability and predisposes for myelodysplasia, myeloid leukemia and solid tumors such as squamous cell carcinomas.^[@bib100]^ Recently, expression of Fanconi anemia genes in the context of truncated vs full-length p53 was investigated in a mouse model. A truncated variant of p53 missing the C-terminal 31 amino acids was employed and its transcriptional program in comparison with full-length p53 was tested.^[@bib101]^ The p53Δ31 mutant lacks the C-terminal domain which interferes with DNA binding reducing p53 activity.^[@bib102]^ Thus, p53Δ31 displays elevated transcriptional activity compared with full-length p53 resulting in enhanced *p21/CDKN1A* activation and concomitant induction of the p53--DREAM pathway.^[@bib39],\ [@bib101]^ It was shown that several Fanconi anemia genes are repressed by p53, bind E2F4 after induction of p53 and contain candidate CDE/CHR sites in their promoters ([Table 2](#tbl2){ref-type="table"}). Detailed analyses were performed with *FANCD2, FANCI* and *RAD51 (FANCR)* by testing mutants of CDE/CHR sites in their promoters.^[@bib101]^ Consistently, all Fanconi anemia genes which were experimentally confirmed to be controlled through DREAM had also been predicted by bioinformatic analyses as DREAM targets^[@bib17],\ [@bib101]^ ([Table 2](#tbl2){ref-type="table"}). These data suggest that an entire group of functionally related genes is coordinately downregulated by the p53--DREAM pathway. The coordinate regulation of whole functional groups implies that the p53--DREAM pathway controls not just a partial aspect but an entire function of a cell ([Figure 4](#fig4){ref-type="fig"}).

Another group of genes associated with telomere maintenance partially overlaps with the Fanconi anemia gene family as some genes from both groups are involved in DNA repair.^[@bib101]^ The telomere-related *DKC1* (Dyskerin)*, RTEL1* and *TINF2* genes are found mutated in *dyskeratosis congenita.* From the meta-analysis data it is unclear whether they are also DREAM targets^[@bib17],\ [@bib101]^ ([Table 2](#tbl2){ref-type="table"}). However, many genes with functions in telomere maintenance, length or replication as well as DNA repair -- e.g. *DEK, FEN1, RECQL4, TIMELESS, BLM, RIF1, ACD, RPA2, WRAP53 (TCAB1)*, *TRAIP* and *PIF1 (RRM3)* -- are indirectly downregulated by p53. Correspondingly, binding of DREAM components to these genes was observed by genome-wide ChIP experiments, again indicating that a functionally related gene set is controlled by the p53--DREAM pathway^[@bib17],\ [@bib101],\ [@bib103],\ [@bib104]^ ([Table 2](#tbl2){ref-type="table"}).

Also breast and ovarian cancer susceptibility genes *BRCA1* and *BRCA2* are among the genes implied as DREAM targets by observations from several genome-wide screens.^[@bib17]^ *BRCA1* and *BRCA2* were originally described as Fanconi complementation groups FANCS and FANCD1, respectively.^[@bib100]^ This identity has been challenged recently.^[@bib105]^ Yet, downregulation of these genes by p53 and binding of DREAM components has been shown in a compilation of genome-wide expression and ChIP protein binding data.^[@bib17]^ Furthermore, before the discovery of mammalian DREAM, observations suggested that E2F4, p130 and p107 can bind at the *BRCA1* promoter after induction of hypoxia.^[@bib106]^ p53-dependent repression of *BRCA1* and binding of E2F4 to the gene was later confirmed.^[@bib107]^

In general, these data suggest that gene groups representing pathways controlling important cell functions such as cell cycle checkpoint regulation, DNA repair, telomere maintenance and other functions are coordinately regulated by the p53--DREAM pathway ([Figure 4](#fig4){ref-type="fig"}). Again, this implies that p53 employs DREAM to exert its master regulator function by controlling entire sets of genes responsible for complete cell functions.

Cancer treatment: CDK Inhibitor Drugs and Rescue of the p53--DREAM Pathway
==========================================================================

Cell cycle checkpoint control is in the focus of cancer treatment. Prominent examples for drugs targeting the cell cycle are Palbociclib (PD-0332991, tradename: Ibrance), Abemaciclib (LY2835219) and Ribociclib (LEE 011, Kisqali).^[@bib108]^ Palbociclib was the first of these small-molecule inhibitors to obtain FDA approval for the treatment of breast cancer. The drugs inhibit CDK4/6 cell cycle kinases and compensate for the loss of checkpoint control in cancerous cells. The CDK inhibitors were originally aimed at primarily decreasing pRB phosphorylation in order to promote formation pRB/E2F transcriptional repressor complexes. The classical view is that hypophosphorylation of pRB is an important step in G~1~/S checkpoint control.^[@bib58],\ [@bib108]^

However, it has been established early -- analogous to pRB itself -- that the pRB-related proteins p107 and p130 are substrates for cyclin D/CDK4/6-dependent phosphorylation.^[@bib109],\ [@bib110]^ Thus, inhibition by drugs such as Palbociclib will lead to DREAM formation and cause downregulation of its target genes. As DREAM controls genes which are required for G~1~/S transition, the G~2~/M checkpoint and for progression through mitosis ([Table 1](#tbl1){ref-type="table"}), CDK inhibitors such as Palbociclib will address several cell cycle checkpoints by causing DREAM formation. This suggests that the therapeutic effect of the CDK inhibitors may depend on DREAM.

Human Papilloma Virus HPV E7 -- Destruction of DREAM Function
=============================================================

Human papilloma virus (HPV)-16 E7 has been shown to bind the retinoblastoma protein pRB and impair its tumor-suppressive function.^[@bib111]^ Consistently, also DREAM was reported to be disrupted by E7 binding to the pRB-related protein p130.^[@bib112]^ Moreover, it is established that HPV E6 targets p53 for ubiquitin-mediated destruction.^[@bib113]^ Also, the HPV E7 protein will compromise the function of p53 as a tumor suppressor through binding to the DREAM components p107 and p130. A genome-wide study listed the genes with their change in expression following HPV E7 protein expression.^[@bib114]^ In a report on *PLK4* transcription, we showed in regard to the mechanism that transcriptional deregulation by HPV E7 is mediated through the DREAM complex and CDE/CHR elements in the promoter of the gene.^[@bib69]^ In general, these results implied that all genes controlled by DREAM through E2F or CHR sites in their promoters are deregulated by HPV E7.^[@bib69]^ This notion emerged also from earlier data sets and a recent report on gene deregulation upon E7 expression in keratinocytes.^[@bib69],\ [@bib114],\ [@bib115]^ In a recent genome-wide meta-analysis we identified more than 90 genes, mostly coding for cell cycle regulators, which are upregulated following E7 expression.^[@bib116]^ Thus, these data suggest that deregulation of DREAM substantially contributes to HPV E7-mediated tumorigenesis.

DREAM and Epigenetics
=====================

DREAM also regulates genes involved in DNA methylation, nucleosome formation and histone modification, including *CHAF1A, EZH2, H2AFX, KMT5A, SMCHD1* and *SUZ12* ([Table 1](#tbl1){ref-type="table"}). Recently, it was shown that p53-dependent regulation of enzymes is required for DNA methylation homeostasis.^[@bib117]^ In p53-deficient cells, an imbalance in DNA methylation causes clonal heterogeneity in naïve embryonal stem cells and upon differentiation. The DNA methyltransferase gene *DNMT3B* contributes to DNA methylation homeostasis and appears to be -- according to meta-analysis data -- downregulated by the p53--DREAM pathway ([Table 1](#tbl1){ref-type="table"}). Thus, with their role in epigenetics, DREAM and the p53--DREAM pathway contribute to gene regulation on a global level.

Implications of the p53--p21--DREAM--E2F/CHR pathway
====================================================

p53 is a key mediator of cell cycle arrest in response to cellular stress. With the plethora of genes downregulated by the p53--DREAM pathway, it has become likely that this signaling pathway is central to cell cycle arrest ([Table 1](#tbl1){ref-type="table"}). Considering that regulator functions of these genes span from the G~1~ phase to the end of mitosis, it is evident that p53-dependent cell cycle arrest is not restricted to G~1~/S transition but is also important for all checkpoints up to the completion of cell division ([Figure 4](#fig4){ref-type="fig"}).

An unresolved issue in cell cycle checkpoint control is how functions of pRB and DREAM differ or overlap. Both pRB/E2F complexes and DREAM bind DNA through E2F sites. However, DREAM also employs CHR elements without E2F sites. Thus, gene sets controlled by pRB/E2F or DREAM will overlap but a separate set will be controlled by DREAM and CHR sites ([Figure 2](#fig2){ref-type="fig"}). It has been shown that pRB and p21/CDKN1A have additive effects on G~1~ phase regulation, which may suggest that pRB and DREAM are both required to control G~1~/S transition.^[@bib118]^ Consistently, triple knockout cells for the pRB-related genes cannot undergo cell cycle arrest, in contrast to *Rb−/−* single or *p130−/− p107−/−* double knockout cells which still arrest.^[@bib119]^ Genome-wide expression and protein/DNA binding studies will be instrumental in defining the distinct functions of pRB and p130/p107 -- and thus DREAM.^[@bib65]^

Another feature of the DREAM pathway may be quality of the induced cell cycle arrest. While transcriptional regulation of cell cycle proteins is slower than regulation via, for example, phosphorylation as employed by other pathways, the response to the p53--DREAM pathway may be more sustained, possibly leading to senescence as an irreversible cell cycle arrest or to induction of apoptosis.^[@bib2],\ [@bib6],\ [@bib74]^

The function of many oncogenic factors is to stimulate cell division or, as seen from another perspective, to counteract cell cycle arrest. Consistently, p53 functions as a tumor suppressor through the p53--DREAM pathway by downregulating many oncogenic proteins such as B-Myb, FOXM1, Cyclin B1/2 and CDK1/2 ([Table 1](#tbl1){ref-type="table"}). Thus, many of the genes repressed by p53 are found overexpressed in tumors once the p53--DREAM pathway is impaired. Expression signatures for many cancer types comprises genes downregulation by the p53--DREAM pathway.^[@bib120]^ In numerous studies on many cancer types, p53--DREAM targets head the list of signature genes whose aberrant expression is predictive for poor clinical outcome of cancer patients.^[@bib121],\ [@bib122],\ [@bib123]^ Considering that CDK inhibitors promote repression of these genes by DREAM, functional defects of p21/CDKN1A or upstream pathway elements can be attenuated by these drugs.

In summary, the p53--p21--DREAM--E2F/CHR pathway downregulates a plethora of cell cycle genes, contributes to cell cycle arrest and is a target for cancer therapy. Researchers working on p53 function, cell cycle regulation or cancer treatment may soon join in saluting: We have a DREAM!
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![Cell cycle and transcription factor complexes. The protein complexes binding to DNA change during the cell cycle. Gene expression is repressed in the early phases of the cell cycle and becomes activated during the later phases. For this change, E2F and CHR (cell cycle genes homology region) promoter elements switch from repressor to activator sites. In G~0~ and early G~1~ phase the DREAM complex binds E2F, CHR, CDE (cell cycle-dependent element), and CLE (CHR-like element) sites to repress transcription. In G~2~ phase and mitosis transcriptional repression is released and activation occurs via CHR sites. Only promoters with CHR sites can bind the MuvB-based complexes MMB (B-MYB-MuvB), FOXM1-MMB and FOXM1-MuvB. The MuvB core complex is composed of LIN9, LIN37, LIN52, LIN54 and RBBP4 proteins. LIN54 is the component which binds to CHR elements. For the switch from repressing to activating complexes, B-MYB and FOXM1 are recruited to the MuvB core when E2F4-5/DP and p107/p130 dissociate from the complex. B-MYB-MuvB (MMB), FOXM1-MMB and FOXM1-MuvB complexes serve as activators of late cell cycle genes which carry functional CHR elements. Early cell cycle genes with maximum expression in the S phase are activated by E2F1-3/DP heterodimers through E2F sites](cdd2017172f1){#fig1}

![Modes of DREAM binding. DREAM can form two distinct contacts with DNA. It can bind to DNA via single E2F (**a**) or CHR (**b**) sites. E2F sites are contacted through E2F4-5/DP heterodimers. Distinct from this binding, contacts to CHR elements are made via the LIN54 protein. In the figure, the LIN54 component of the MuvB core complex is the only constituent that is labeled. Binding to E2F or CHR elements can be supported by CLE (**c**) or CDE (**d**) sites, respectively. CDE and CLE sites differ from E2F and CHR elements as CDE and CLE sites are unable to bind DREAM as single elements](cdd2017172f2){#fig2}

![The p53--p21--DREAM--E2F/CHR pathway. Indirect p53-dependent repression through DREAM. Induction of p53 leads to downregulation of genes. This regulation is indirect as p53 does not bind to the regulated genes. Instead, induction of *p21/CDKN1A* expression by p53 causes hypophosphorylation of p107 and p130. Hypophosphorylation of these pRB-related pocket proteins facilitates DREAM formation. DREAM complexes then displace the activating complexes FOXM1--B-MYB-MuvB (FOXM1-MMB) and E2F1-3/DP on the target promoters. (In the figure, LIN54 is the only labeled MuvB component.) Overall, this switch causes previously activated genes to be indirectly downregulation by p53](cdd2017172f3){#fig3}

![Cellular functions of the p53--p21--DREAM--E2F/CHR pathway. In order to summarize cellular functions regulated by the pathway, gene ontology terms for p53--p21--DREAM--E2F/CHR targets from [Table 1](#tbl1){ref-type="table"} were compiled](cdd2017172f4){#fig4}

###### Genes regulated by the p53--DREAM pathway

  **Genes regulated by the p53--DREAM pathway**                                                                                                                                      
  ------------------------------------------------------------------------ --------------------- ------------------------------- --------------------------------------------------- ------------------
  Adrenocortical dyspl. pr. hom., shelterin compl. sub. telom. recruit.    ACD                   Complex form., DNA binding      Telomere maintenance                                ACD
  Anillin, actin-binding protein anillin                                   anillin               Actin binding                   Mitosis                                             ANLN
  Rho GTPase-activating protein 11A                                        ARHGAP11A             GTPase activator activity       Small GTPase-mediated signal transduction           ARHGAP11A
  Rho GTPase-activating protein 11B                                        ARHGAP11B             Rho GTPase activation           Small GTPase-mediated signal transduction           ARHGAP11B
  Rho guanine nucleotide exchange factor 39, C9orf100                      ARHGEF39              Rho guanyl-nucleotide exch.     Cell migration, Rho protein signal transduction     ARHGEF39
  ADP-ribosylation factor-like protein 13B                                 ARL13B                GTP binding                     Cilium assmb., small GTPase signal transduction     ARL13B
  ADP-ribosylation factor-like protein 6-interacting protein 1             ARL6IP1               Chromosomal pass. complex       Cotranslational protein targeting to membrane       ARL6IP1
  Anti-silencing function 1B histone chaperone                             ASF1B                 Histone chaperone               Chromatin assembly, DNA replication                 ASF1B
  Abnormal spindle-like microcephaly-associated protein                    ASPM                  Complex formation               Spindle assembly, mitosis, neurogenesis             ASPM, MCPH5
  ATPase family AAA domain-containing protein 2                            ATAD2                 ATPase                          Transcriptional coactivator                         ATAD2
  Aurora kinase A                                                          AURKA                 Serine/threonine kinase         Spindle/microtubule formation, mitosis              AURKA
  Aurora kinase B                                                          AURKB                 Serine/threonine kinase         Cytokinesis, histone modification, mitosis          AURKB
  BLM, Bloom syndrome RecQ like helicase                                   BLM                   DNA helicase                    DNA replication and repair                          BLM
  MYB proto-oncogene like 2                                                B-MYB, MYBL2          Transcription factor            S phase, activator                                  MYBL2
  Borealin, CDCA8                                                          Borealin, CDCA8       Complex formation               Chromosomal passenger complex, spindle form.        CDCA8, Borealin
  BRCA1, Breast cancer type 1 susceptibility protein                       BRCA1                 Ubiquitin ligase                DNA repair, transcription, ubiquitination           BRCA1, FANCS
  BRCA2, Breast cancer type 2 susceptibility protein                       BRCA2                 Complex formation               DNA repair, transcription                           BRCA2, FANCD1
  BRIP1, BRCA1 interacting protein C-terminal helicase 1                   BRIP1, BACH1          DNA helicase and ATPase         DNA replication and repair                          BRIP1, FANCJ
  BUB1, mitotic checkpoint serine/threonine kinase                         BUB1                  Serine/threonine kinase         Spindle formation, mitosis                          BUB1
  BUB3, mitotic checkpoint protein                                         BUB3                  Protein binding, WD repeats     Spindle formation, mitosis                          BUB3
  BUB1, mitotic checkpoint serine/threonine kinase B                       BUBR1, BUB1B          Serine/threonine kinase         Spindle formation, mitosis                          BUB1B, BUBR1
  Calcyclin-binding protein                                                CACYBP                Complex formation               Ubiquitin-mediated degradation of beta-catenin      CACYBP
  Cancer susceptibility candidate 5, Kinetochore-null protein 1            CASC5, KNL1           Protein binding                 Kinetochore, spindle formation, mitosis             KNL1, CASC5
  Chromobox protein homolog 3, Heterochromatin prot. 1 hom. gam.           CBX3, HECH            Histone binding                 Transcription, histone methyltransferase binding    CBX3
  Coiled-coil domain-containing protein 150                                CCDC150                                                                                                   CCDC150
  Coiled-coil domain-containing protein 18, Sarco antig NY-SAR-24          CCDC18                                                                                                    CCDC18
  Coiled-coil domain-containing protein 34, Ren carc ant NY-REN-41         CCDC34                                                                                                    CCDC34
  CDC20, Cell division cycle protein 20                                    CDC20, p55CDC         Complex formation               mitotic spindle assembly checkpoint, mitosis        CDC20, p55CDC
  CDC20, cell division cycle 25A, M-phase inducer phosphatase 1            CDC25A                Tyrosine phosphatase            G1/S and G2/M transition                            CDC25A
  CDC25B, Cell division cycle 25B, M-phase inducer phosphatase 2           CDC25B                Tyrosine phosphatase            G2/M phases and abscission during cytokinesis       CDC25B
  CDC25C, cell division cycle 25C, M-phase inducer phosphatase 3           CDC25C                Tyrosine phosphatase            G2/M phases and abscission during cytokinesis       CDC25C
  CDC6, cell division cycle 6                                              CDC6                                                  G1/S transition, DNA replication                    CDC6
  CDC7, cell division cycle 7                                              CDC7                  Protein kinase                  G1/S transition                                     CDC7
  CDCA2, cell division cycle-associated protein 2, Repo-Man                CDCA2                 Complex formation               Chromosome segregation                              CDCA2
  Cell division cycle-assoc. prot. 3, trigger of mitotic entry protein 1   CDCA3, TOME-1         F-box-like protein              Protein ubiquitination                              CDCA3, TOME-1
  CDK1, cyclin-dependent kinase 1, cdc2                                    CDK1, CDC2            Serine/threonine kinase         G1/S and G2/M transition                            CDK1, CDC2
  CDK2, cyclin-dependent kinase 2                                          CDK2                  Serine/threonine kinase         G1/S and G2/M transition                            CDK2
  CDKN2D, cyclin-dependent kinase 4 inhibitor D, p19-INK4d                 CDKN2D, p19           CDK4/6 inhibitor                G1/S transition                                     CDKN2D
  CDKN3, cyclin-dependent kinase inhibitor 3, CDI1, CIP2, KAP              CDKN3, CIP2           CDK2 phosphatase                Regulation of cyclin-dependent kinase activity      CDKN3
  Chromatin licensing and DNA replication factor 1                         CDT1                  Chromatin binding               DNA replication, mitosis                            CDT1
  CENP-A, Histone H3-like centromeric protein A                            CENP-A                Chromatin binding               Nucleosome and kinetochore assembly                 CENPA
  CENP-C, centromere protein C                                             CENP-C                Kinetochore binding             Microtubule function, cytokinesis, mitosis          CENPC
  CENP-E, centromere protein E                                             CENP-E                Kinetochore binding             Microtubule function, cytokinesis, mitosis          CENPE
  CENP-F, centromere protein F, Mitosin                                    CENP-F, Mitosin       Kinetochore binding             Microtubule function, cytokinesis, mitosis          CENPF, CENF
  CENP-L, centromere protein L                                             CENP-L, ICEN33        Chromatin binding               Nucleosome and kinetochore assembly                 CENPL, ICEN33
  CENP-N, centromere protein N                                             CENP-N, ICEN32        Chromatin binding               Nucleosome and kinetochore assembly                 CENPN, ICEN32
  CENP-O, centromere protein O                                             CENP-O                Complex formation               Nucleosome assembly, centromere, mitosis            CENPO
  CENP-W, centromere protein W                                             CENP-W                Complex formation               Nucleosome assembly, centromere, mitosis            CENPW
  CEP55, centrosomal protein of 55 kDa                                     CEP55                 Complex formation               Mitotic exit, cell separation after cytokinesis     CEP55
  CEP152, centrosomal protein of 152 kDa                                   CEP152                Protein kinase binding          Centriole and centrosome duplication                CEP152
  CEP295, centrosomal protein 295, DD8                                     CEP295, DD8           Complex formation               centrosome, microtubules, cytoskeleton, cilium      CEP295, KIAA1731
  CHAF1A, chromatin assembly factor 1 subunit A                            CHAF1A                Histone binding                 Histone octamer assembly, chromatin, replicat.      CHAF1A
  CHEK1, checkpoint kinase 1                                               CHEK1                 Serine/threonine kinase         DNA damage response, G2/M transition                CHEK1
  CHEK2, checkpoint kinase 2                                               CHEK2                 Serine/threonine kinase         DNA damage response, G2/M transition                CHEK2
  CIP2A, cancerous inhibitor of protein phosphatase 2A                     CIP2A                 Phosphatase inhibitor           Oncoprotein, cell adhesion, transcription           KIAA1524, CIP2A
  CIT, Citron Rho-interacting kinase                                       CIT, CRIK             Serine/threonine kinase         Cytokinesis, GTPase signal transduction             CIT, CRIK
  Cytoskeleton-associated protein 2, tumor- and microtub.-assoc.           CKAP2, TMAP           Microtubule stabilizing         Apoptotic process, microtubule polymerization       CKAP2
  CKAP2L, cytoskeleton-associated protein 2-like, Radmis                   CKAP2L, Radmis        Complex formation               Microtubule bundles, centrioles during mitosis      CKAP2L
  CKAP5, cytoskeleton-associated protein 5                                 CKAP5                 Microtubule binding             Microtubule cytoskeleton polarity, spindle pole     CKAP5
  Cyclin-dependent kinases regulatory subunit 1, CDC28 kin sub 1B          CKS-1, CKS-1B         Cyclin-dep. kinase binding      G1/S transition, CDK binding                        CKS1B, CKS1
  CKS-2, cyclin-dependent kinases regulatory subunit 2                     CKS-2                 Cyclin-dep. kinase binding      Meiosis I, CDK binding                              CKS2
  CMS1, ribosomal small subunit homolog                                    CMSS1, CMS1           Poly(A) RNA binding             Poly(A) RNA binding                                 CMSS1
  CTD small phosphatase-like protein 2                                     CTDSPL2               Protein phosphatase             BMP signaling pathway, transport from nucleus       CTDSPL2
  Cyclin A                                                                 Cyclin A, cyclin A2   Complex formation               Serine/threonine kinase activation, mitosis         CCNA, Ccna2
  Cyclin B1                                                                cyclin B1             Complex formation               Serine/threonine kinase activation, mitosis         CCNB1
  Cyclin B2                                                                Cyclin B2             Complex formation               Serine/threonine kinase activation, mitosis         CCNB2
  DAP-5, Disks large-associated protein 5                                  DAP-5, DLGAP5                                         Metaphase/anaphase transition, ubiqutination        DLGAP5, DLG7
  DARS2, Aspartate-tRNA ligase, mitochondrial                              DARS2                 Aspartate-tRNA ligase           Gene expression, aminoacylation for translation     DARS2
  Protein DBF4 homolog B, activator of S phase kinase-like prot. 1         DBF4B, ASKL1          CDC7 kinase activation          DNA replication, G2/M transition                    DBF4B, DRF1
  DCAF16, DDB1- and CUL4-associated factor 16                              DCAF16                Protein ubiquitination          Protein ubiquitination                              DCAF16
  DCK, deoxycytidine kinase                                                DCK                   Nucleoside kinase               Nucleotide biosynthetic process                     DCK
  DCLRE1B, 5\' exonuclease Apollo                                          DCLRE1B, APOLLO       5\'--3\' DNA exonuclease        Telomere maintenance, double-strand br. rep.        DCLRE1B
  DCP2, m7GpppN-mRNA hydrolase                                             DCP2                  mRNA-decapping enzyme           Regulation of mRNA stability, gene expression       DCP2
  DNA damage-induced apoptosis suppressor, NO-inducible prot.              DDIAS, NOXIN                                          Apoptosis, DNA damage resp., cell cycle arrest      DDIAS, NOXIN
  DDX10, ATP-dependent RNA helicase DDX10                                  DDX10                 RNA helicase                    RNA secondary structure unwinding                   DDX10
  DEK, proto-oncogene                                                      DEK                   Histone binding                 Chromatin modification, mRNA processing             DEK
  DEPDC1, DEP domain-containing protein 1A                                 DEPDC1                Transcriptional corepressor     GTPase activator activity, transcription            DEPDC1
  DEPDC1B, DEP domain-containing protein 1B                                DEPDC1B               GTPase activator activity       Cell migration, Wnt signaling pathway, GTPase       DEPDC1B, XTP1
  Dihydrofolate reductase                                                  DHFR                  Oxidoreductase                  DNA synthesis                                       DHFR
  DLEU1, Leukemia-associated protein 1                                     DLEU1                                                                                                     DLEU1, XTP6
  DNMt3B, DNA methyltransferase 3 beta                                     DNMT3B                Methyltransferase               Chromatin binding, transcriptional corepressor      DNMT3B
  E2F1, E2F transcription factor 1                                         E2F1                  Transcription factor            Cell cycle                                          E2F1
  ECT2, epithelial cell transforming 2                                     ECT2                  GTPase                          Cytokinesis, spindle formation, mitosis             ECT2
  establishment of sister chromatid cohesion *N*-acetyltransferase 2       ESCO2                 Lysine N-acetyltransferase      Chromosome segregation                              ESCO2
  EXO1, Exonuclease 1                                                      EXO1                  DNA nuclease                    DNA repair, recombination, replication              EXO1
  EXOSC8, exosome component 8                                              EXOSC8                Exoribonuclease                 RNA degradation                                     EXOSC8
  EXOSC9, exosome component 9                                              EXOSC9                Complex formation               RNA degradation                                     EXOSC9
  Exportin-2, CSE1 chromosome segregation 1-like                           Exportin-2            Export receptor importin-a      Protein transport from/to nucleus                   CSE1L
  Histone-lysine N-methyltransferase, enhancer of zeste 2 polycomb         EZH2                  Lysine *N*-methyltransferase    Histone modification, chromatin organization        EZH2
  FAM64A, family with sequence similarity 64 member A                      FAM64A                Complex formation               Mitosis                                             FAM64A
  FAM83D, family with sequence similarity 83 member D                      FAM83D                Complex formation               Mitosis                                             FAM83D
  FANCA, Fanconi anemia complementation group A                            FANCA                 Complex formation               Fanconi anemia, DNA repair                          FANCA
  FANCB, Fanconi anemia complementation group B                            FANCB                 Complex formation               Fanconi anemia, DNA repair                          FANCB
  FANCC, Fanconi anemia complementation group C                            FANCC                 Complex formation               Fanconi anemia, DNA repair                          FANCC
  FANCD2, Fanconi anemia complementation group D2                          FANCD2                Complex formation               Fanconi anemia, DNA repair                          FANCD2
  FANCE, Fanconi anemia complementation group E                            FANCE                 Complex formation               Fanconi anemia, DNA repair                          FANCE
  FANCG, Fanconi anemia complementation group G                            FANCG                 Complex formation               Fanconi anemia, DNA repair                          FANCG
  FANCI, Fanconi anemia complementation group I                            FANCI                 DNA binding, complex form.      Fanconi anemia, DNA repair                          FANCI
  FANCL, Fanconi anemia complementation group L                            FANCL                 Ubiquitin ligase                Fanconi anemia, DNA repair                          FANCL
  FANCM, Fanconi anemia complementation group M                            FANCM                 ATPase, DNA binding             Fanconi anemia, ubiquitination, DNA repair          FANCM
  FBXO5, F-box protein 5, Early mitotic inhibitor 1, EMI1, FBX5            FBXO5                 Complex formation               Mitosis                                             FBXO5
  FEN1, flap structure-specific endonuclease 1                             FEN1                  DNA nuclease                    DNA repair                                          FEN1, RAD2
  FOXM1, forkhead box M1                                                   FOXM1                 Transcription factor            G2 phase, mitosis, activator                        FOXM1
  FZR1, fizzy/cell division cycle 20 related 1                             FZR1                  Activator of ubiquitination     Mitosis, anaphase promoting complex/cyclos.         FZR1
  G2E3, G2/M-phase specific E3 ubiquitin protein ligaseprovided            G2E3                  Ubiquitin ligase                G2 phase, mitosis                                   G2E3
  GASL2L3, growth arrest specific 2 like 3                                 GAS2L3                Complex formation               Cytokinesis                                         GAS2L3
  GPSM2, G-protein signaling modulator 2provided                           GPSM2                 GDP-dissociation inhibitor      G-protein coupled receptor sign., mitotic spindle   GPSM2
  GTSE1, G2 and S-phase expressed 1                                        GTSE1                 Complex formation               Microtubule organization                            GTSE1
  histone, H2A histone family member X                                     H2AFX, H2AX           Histone                         Nucleosome formation, DNA repair                    H2AFX
  histone, H2A histone family member Z                                     H2AFZ, H2AZ           Histone                         Nucleosome formation, embryonic development         H2AFZ
  haspin, germ cell associated 2                                           haspin, GSG2          Serine/threonine kinase         Mitosis, microtubule organization                   GSG2
  HAUS augmin like complex subunit 6                                       HAUS6                 Complex formation               Cytokinesis, spindle assembly                       HAUS6
  HAUS augmin like complex subunit 8                                       HAUS8, HICE1          Complex formation               Cytokinesis, spindle assembly                       HAUS8
  histone cluster 1 H2A family member e                                    HIST1H2AE, H2A.1      Histone                         Nucleosome formation                                HIST1H2AE
  histone cluster 1 H2A family member m                                    HIST1H2AM             Histone                         Nucleosome formation                                HIST1H2AM
  histone cluster 1 H2B family member f                                    HIST1H2BF             Histone                         Nucleosome formation                                HIST1H2BF
  histone cluster 1 H2B family member h                                    HIST1H2BH             Histone                         Nucleosome formation                                HIST1H2BH
  histone cluster 1 H2B family member i                                    HIST1H2BI             Histone                         Nucleosome formation                                HIST1H2BI
  histone cluster 1 H2B family member m                                    HIST1H2BM             Histone                         Nucleosome formation                                HIST1H2BM
  histone cluster 1 H3 family member c                                     HIST1H3C              Histone                         Nucleosome formation                                HIST1H3C
  histone cluster 1 H3 family member d                                     HIST1H3D              Histone                         Nucleosome formation                                HIST1H3D
  histone cluster 1 H4 family member c                                     HIST1H4C              Histone                         Nucleosome formation                                HIST1H4C
  histone cluster 2 H2A family member b                                    HIST2H2AB             Histone                         Nucleosome formation                                HIST2H2AB
  histone cluster 2 H2A family member c                                    HIST2H2AC             Histone                         Nucleosome formation                                HIST2H2AC
  Holliday junction recognition protein                                    HJURP                 DNA binding, chaperone          Centromere, nucleosome assembly                     HJURP
  HMGB2, High mobility group protein B2                                    HMGB2, HMG2           DNA binding                     Chromatin, transcription, recombination             HMGB2
  HMMR, Receptor for hyaluronan-med. motility, RHAMM, CD168                HMMR, RHAMM           Complex formation               Cell adhesion, mitosis, hyaluronic acid binding     HMMR, RHAMM
  HNRNPA0, heterogeneous nuclear ribonucleoprotein A0                      HNRNPA0               RNA binding                     mRNA processing                                     HNRNPA0
  HNRNPA2B1, heterogeneous nuclear ribonucleoprotein A2/B1                 hnRNP A2/B1           RNA binding                     RNA and single-stranded telomeric DNA binding       HNRNPA2B1
  BORA, Aurora kinase A activator, protein aurora borealis                 HsBora                Kinase binding                  Spindle/microtubule formation, mitosis              BORA
  IFT80, intraflagellar transport 80                                       IFT80                 Complex formation               Cilia assembly                                      IFT80
  INCENP, inner centromere protein                                         INCENP                Complex formation               Cytokinesis, centromere, microtubule binding        INCENP
  ING1, inhibitor of growth family member 1                                ING1                  Complex formation               p53 interaction, tumor suppr., chromatin            ING1
  Ki-67                                                                    Ki-67                 Complex formation               Mitotic chromosome stabilization                    MKI67
  KIF11, kinesin family member 11                                          KIF11, EG5            Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF11, EG5
  KIF14, kinesin family member 14                                          KIF14                 Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF14
  KIF15, kinesin family member 15                                          KIF15                 Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF15
  KIF18A, kinesin family member 18A                                        KIF18A                Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF18A
  KIF20B, kinesin family member 20B, M-phase phosphoprotein-1              KIF20B, MPP1          Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF20B, MPP1
  KIF22, kinesin family member 22                                          KIF22, KID            Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF22, KID
  KIF23, kinesin family member 23, Mitotic kinesin-like protein 1          KIF23, MKLP1          Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF23, MKLP1
  KIF24, kinesin family member 24                                          KIF24                 Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF24
  KIF2C, kinesin family member 2C, Mitotic centromere-ass. kinesin         KIF2C, MCAK           Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF2C
  KIF4A, kinesin family member 4A                                          KIF4A, KIF4           Microtubule binding             Microtubule function, cytokinesis, mitosis          KIF4A
  KIFC1, kinesin family member C1                                          KIFC1                 ATPase                          Microtubule motor activity, spindle assembly        KIFC1
  KPNA2, Importin subunit alpha-1, karyopherin subunit alpha 2             KPNA2                 Protein transporter             Nuclear protein import, recombination               KPNA2
  KPNB1, Importin subunit beta-1, karyopherin subunit beta 2               KPNB1                 Protein transporter             Nuclear protein import                              KPNB1
  lamin B1                                                                 lamin B1              Lamin                           Nuclear lamina                                      LMNB1
  Acidic leucine-rich nuclear phosphoprotein 32 family member E            LANP-like protein     Histone chaperone               Histone exchange, chromatin modification            ANP32E
  LIN-54 DREAM MuvB core complex component                                 LIN54                 DNA binding                     Transcription, activator, repessor, cell cycle      LIN54
  LIN-9 DREAM MuvB core complex component                                  LIN9                  complex, transcription          transcription, activator, repessor, cell cycle      LIN9
  LSM5, U6 snRNA-associated Sm-like protein LSm5                           LSM5                  RNA binding                     mRNA processing                                     LSM5
  MAD2, Mitotic spindle assembly checkpoint protein MAD2A                  MAD2                  Complex formation               Mitotic spindle assembly checkpoint, mitosis        MAD2L1, MAD2
  MAD3, Max dimerization protein 3                                         MAD3, MXD3            Transcription factor            MYC/MAX-related, repressor                          MXD3
  GREATWALL, microtubule associated serine/threonine kinase like           MASTL                 Serine/threonine kinase         G2 phase, mitosis                                   MASTL
  MCM2, minichromosome maintenance complex component 2                     MCM2                  Complex formation, ATPase       DNA helicase, replication                           MCM2
  MCM3, minichromosome maintenance complex component 3, HCC5               MCM3, HCC5            Complex formation, ATPase       DNA helicase, replication                           MCM3
  MCM4, minichromosome maintenance complex component 4                     MCM4                  Complex formation, ATPase       DNA helicase, replication                           MCM4
  MCM5, minichromosome maintenance complex comp. 5, CDC46                  MCM5, CDC46           Complex formation, ATPase       DNA helicase, replication                           MCM5
  MCM6, minichromosome maintenance complex component 6, Mis5               MCM6, Mis5            Complex formation, ATPase       DNA helicase, replication                           MCM6
  MCM7, minichromosome maintenance complex comp. 7, CDC47                  MCM7, CDC47           Complex formation, ATPase       DNA helicase, replication                           MCM7
  MCM8, minichromosome mainten. 8 homolog. recomb. repair factor           MCM8                  Complex formation, ATPase       Helicase, replication, homolog. recomb. repair      MCM8
  MDC1, mediator of DNA damage checkpoint 1                                MDC1                  Complex formation               DNA repair, checkpoint control, S, G2, M phase      MDC1
  MELK1, maternal embryonic leucine zipper kinase                          MELK                  Serine/threonine kinase         Apoptosis, G2/M transition                          MELK
  METTL4, methyltransferase like 4                                         METTL4                DNA Methyltransferase           DNA methylation, adenine-specific                   METTL4
  MIS18, kinetochore protein A                                             MIS18A                Complex formation               Centromere complexes, chromosome segregat.          MIS18A
  MIS18BP1, MIS18 binding protein 1                                        MIS18BP1              Complex formation               Centromere complexes, chromosome segregat.          MIS18BP1
  MND1, meiotic nuclear divisions 1                                        MND1                  DNA binding                     Meiosis, DNA recombination                          MND1
  MSH2, mutS homolog 2, Heredit. non-polyp. color. Canc. 1, HNPCC          MSH2                  Complex formation, ATPase       DNA repair, mismatch repair                         MSH2, HNPCC
  MSH6, mutS homolog 6                                                     MSH6                  Complex formation, ATPase       DNA repair, mismatch repair                         MSH6
  metal response element bind. transcription fact. 2, polycomblike 2       MTF2, PCL2            DNA binding                     Histone binding, transcription, repression          MTF2
  MZT1, Mitotic-spindle organizing protein 1                               MZT1, MOZART1         Complex formation               Tubulin binding, centrosome, spindle assembly       MZT1
  NASP, nuclear autoantigenic sperm protein                                NASP                  Histone binding                 DNA replication                                     NASP
  NCAPD2, condensin, non-SMC condensin I complex subunit D2                NCAPD2                Complex formation               Chromosome condensation, mitosis                    NCAPD2
  NCAPD3, condensin, non-SMC condensin II complex subunit D3               NCAPD3                Complex formation               Chromosome condensation, mitosis                    NCAPD3
  NCAPG, condensin, non-SMC condensin I complex subunit G                  NCAPG                 Complex formation               Chromosome condensation, mitosis                    NCAPG
  NCAPG2, condensin, non-SMC condensin II complex subunit G2               NCAPG2                Complex formation               Chromosome condensation, mitosis                    NCAPG2
  NCAPH, condensin, non-SMC condensin I complex subunit H                  NCAPH                 Complex formation               Chromosome condensation, mitosis                    NCAPH
  NDC1, transmembrane nucleoporin                                          NDC1, TMEM48          Complex formation               Nuclear envelope assembly, nuclear transport        NDC1, TMEM48
  NDC80, kinetochore complex component NDC80                               NDC80                 Complex formation               Chromosome segregation, microtubule binding         NDC80
  NEIL3, nei like DNA glycosylase 3                                        NEIL3                 DNA endonuclease                DNA repair                                          NEIL3
  NEK2, NIMA related kinase 2                                              NEK2                  Serine/threonine kinase         Chromosome condensation, spindle assembly           NEK2
  NET1, neuroepithelial cell transforming 1                                NET1                  Rho guanyl-nucleotide exch.     Apoptosis, signal transduction                      NET1
  NOP58, ribonucleoprotein                                                 NOP58                 Complex formation               Ribosome biogenesis                                 NOP58
  NOXIN, DNA damage-induced apoptosis suppressor                           NOXIN, DDIAS                                          Apoptosis, response to DNA damage, mitosis          C11orf82, DDIAS
  nuclear casein kinase and cyclin-dependent kinase substrate 1            NUCKS1, JC7           DNA binding                     DNA damage response, homologous recomb.             NUCKS1
  NUF2, NDC80 kinetochore complex component                                NUF2, CDCA1           Complex formation               Chromosome segregation, microtubule binding         NUF2
  NUP107, nucleoporin 107                                                  NUP107                Complex formation               Nucleocytoplasmic transport                         NUP107
  NUP205, nucleoporin 205                                                  NUP205                Complex formation               Nucleocytoplasmic transport                         NUP205
  NUP35, nucleoporin 35                                                    NUP35, NUP53          Complex formation               Nucleocytoplasmic transport                         NUP35
  NUP85, nucleoporin 85, Pericentrin-1                                     NUP85                 Complex formation               Nucleocytoplasmic transport                         NUP85
  NUSAP1, nucleolar and spindle associated protein 1                       NUSAP1, SAPL          Complex formation               Mitotic spindle microtubules                        NUSAP1
  OCT1, POU class 2 homeobox 1, Octamer-binding protein 1                  OCT1, POU2F1          Transcription factor            Proliferation, immune modulation                    POU2F1
  OIP5, Opa interacting protein 5                                          OIP5                  Complex formation               Centromere binding, chromosome segregation          OIP5
  ORC1, origin recognition complex subunit 1                               ORC1                  DNA binding                     DNA replication                                     ORC1
  PALB2, partner and localizer of BRCA2                                    PALB2, FANCN          Complex form., DNA bindg.       Fanconi anemia, DNA repair, replication             PALB2, FANCN
  CENP-M, Centromere protein M                                             PANE1, CENP-M         Complex formation               Kinetochore formation, mitosis                      CENPM
  PARPBP, PARP1 binding protein                                            PARPBP                Complex formation               DNA repair, genomic stability                       PARPBP
  pericentrin                                                              Pericentrin           Complex formation               Centrosome, microtubules, cilia assembly            PCNT
  PHF19, PHD finger protein 19                                             PHF19                 Complex formation               Histone binding, transcription, repression          PHF19
  PICH, Plk1-interacting checkpoint helicase                               PICH, ERCC6L          DNA helicase                    DNA repair, spindle assembly, anaphase              ERCC6L
  PIF1, 5\'-to-3\' DNA helicase                                            PIF1                  ATPase, DNA helicase            DNA repair, telomere maintenance                    PIF1
  PLK1, Polo-like kinase 1                                                 PLK1                  Serine/threonine kinase         G2/M transition, mitosis                            PLK1
  PLK4, Polo-like kinase 4                                                 PLK4                  Serine/threonine kinase         G2/M transition, mitosis                            PLK4, SAK
  POC5, centriolar protein                                                 POC5                                                  Centriole elongation                                POC5
  POLA1, DNA polymerase alpha-1, catalytic subunit                         POLA1                 DNA polymerase                  DNA replication                                     POLA1
  POLD1, DNA polymerase delta 1, catalytic subunit                         POLD1                 DNA polymerase, exonucl.        DNA replication, DNA repair                         POLD1
  POLD3, DNA polymerase delta 3, accessory subunit                         POLD3                 DNA polymerase, exonucl.        DNA replication, DNA repair, mismatch repair        POLD3
  POLE, DNA polymerase epsilon, catalytic subunit                          POLE                  DNA polymerase                  DNA replication, DNA repair                         POLE
  POLQ, DNA polymerase theta                                               POLQ                  DNA polymerase                  DNA replication, DNA repair                         POLQ
  POP7 homolog, ribonuclease P/MRP subunit                                 POP7                  Ribonuclease                    tRNA processing                                     POP7
  PPIH, peptidylprolyl isomerase H                                         PPIH                  Peptidylprolyl isomerase        Protein folding, mRNA splicing                      PPIH
  PRC1, protein regulator of cytokinesis 1                                 PRC1                  Complex formation               Cytokinesis, spindle formation, mitosis             PRC1
  PRIM1, primase (DNA) subunit 1                                           PRIM1                 DNA primase, RNA synthesis      DNA replication                                     PRIM1
  PRIM2, primase (DNA) subunit 2                                           PRIM2                 DNA primase                     DNA replication, telomere maintenance               PRIM2
  PRR11, proline rich 11                                                   PRR11                                                 Cell cycle regulation                               PRR11
  Partner of SLD Five 1, DNA replication complex GINS protein PSF1         PSF1, GINS1           DNA helicase                    DNA helicase, replication                           GINS1
  Partner of SLD Five 2, DNA replication complex GINS protein PSF2         PSF2, GINS2           Complex formation               DNA helicase, replication                           GINS2
  PSRC1, proline and serine rich coiled-coil 1                             PSRC1, DDA3           Complex formation               Microtubule polymerization, mitosis                 PSRC1
  Securin, PTTG1, pituitary tumor-transforming 1                           PTTG1, securin        Complex formation               Mitotic spindle assembly checkpoint, mitosis        PTTG1
  RACGAP1, Rac GTPase-activating protein 1                                 RACGAP1               Regulation of small GTPase      Cytokinesis, mitosis                                RACGAP1
  RAD18, E3 ubiquitin protein ligase                                       RAD18                 Ubiquitin ligase                Detection of DNA damage, DNA repair                 RAD18
  RAD21, cohesin complex component                                         RAD21                 Complex formation               Chromosome cohesion, DNA repair, apoptosis          RAD21
  RAD51, recombinase                                                       RAD51, FANCR          DNA-dependent ATPase            Fanconi anemia, DNA repair                          RAD51, FANCR
  RAD54-like                                                               RAD54L                DNA helicase                    DNA repair, mitotic recombination                   RAD54L
  RANGAP1, Ran GTPase-activating protein 1                                 RANGAP1               Ran GTPase activator activity   Nuclear pore complex, kinetochore, mitosis          RANGAP1
  RECQL4, RecQ like helicase 4                                             RECQL4                DNA helicase, ATPase            DNA repair, replication, recombination              RECQL4
  REEP4, receptor accessory protein 4                                      REEP4                 Complex formation               Microtubule bdg, nuclear envelope reassembly        REEP4
  RHINO, RAD9-HUS1-RAD1 interacting nuclear orphan 1                       RHINO                 Complex formation               DNA repair, cellular response to DNA damage         RHNO1, C12orf32
  RIF1, replication timing regulatory factor 1                             RIF1                  Complex formation               DNA repair, checkpoint control, telemore bindg.     RIF1
  RNASEH2A, ribonuclease H2 subunit A                                      RNASEH2A              RNA endonuclease                DNA replication                                     RNASEH2A
  RNF26, ring finger protein 26                                            RNF26                 Ubiquitin ligase                Endosomal maturation and trafficking                RNF26
  RPA2, replication protein A2                                             RPA2                  Complex form., DNA bindg.       DNA repair, replication                             RPA2
  RTKN2, rhotekin 2                                                        RTKN2                 Rho GTPase effector             Cell cycle regulation, apoptosis                    RTKN2
  SAS-6 centriolar assembly protein, Spindle assem. abn. protein 6         SAS6, SASS6           Complex formation               Centrosome duplication, procentriole formation      SASS6
  SCLT1, sodium channel and clathrin linker 1                              SCLT1                 Complex formation               Clathrin binding, cilia assembly                    SCLT1
  Separase, extra spindle pole bodies like 1                               Separase, ESPL1       Protease                        Chromosome segregation                              ESPL1
  SETD8, lysine methyltransferase 5A                                       SETD8, KMT5A          Lysine *N*-methyltransferase    Protein methylation, transcriptional repression     KMT5A, SETD8
  SGO1, shugoshin 1                                                        SGO1, SGOL1           Complex formation               Chromosome segregation, centromere binding          SGOL1, SGO1
  SGO2, shugoshin 2                                                        SGO2, SGOL2           Complex formation               Sister chromatid cohesion, meiosis, centromere      SGOL2, SGO2
  SHCBP1, SHC binding and spindle associated 1                             SHCBP1                                                Cell proliferation                                  SHCBP1
  SKA1, Spindle and kinetochore-associated protein 1                       SKA1                  Complex formation               Kinetochore, microtubules, mitosis                  SKA1
  SKAP, kinetochore localized astrin/SPAG5 binding protein                 SKAP, KNSTRN          Complex formation               Mitotic spindle, chromosome segregation             KNSTRN
  SKP2, S-phase kinase associated protein 2                                SKP2                  F-box-like protein              Protein ubiquitination                              SKP2
  SLC25A40, solute carrier family 25 member 40                             SLC25A40                                              Mitochondrial carrier                               SLC25A40
  SMC-2, structural maintenance of chromosomes 2                           SMC-2                 ATP binding                     DNA condensation, mitosis                           SMC2
  SMC-4, structural maintenance of chromosomes 4                           SMC-4                 ATP binding                     DNA condensation, mitosis                           SMC4
  structural maintenance of chromos. Flex. hinge domain contain. 1         SMCHD1                Complex formation               DNA methylation                                     SMCHD1
  Sororin, CDCA5                                                           Sororin, CDCA5        Chromatin binding               Mitotic sister chromatid cohesion                   CDCA5, Sororin
  Sp4, transcription factor                                                SP4                   Transcription factor            Transcription                                       SP4
  SPAG5, sperm associated antigen 5                                        SPAG5                 Complex formation               Mitotic spindle, chromosome segregation             SPAG5
  SPC25, NDC80 kinetochore complex component                               SPC25                 Complex formation               Chromosome segregation, microtubule binding         SPC25
  Spindly, Coiled-coil domain-containing protein 99                        SPDL1/CCDC99          Kinetochore binding             Establishment of mitotic spindle orientation        SPDL1/CCDC99
  STIL, SCL/TAL1 interrupting locus                                        STIL                                                  Embryonic development, cell proliferation           STIL
  STK17B, serine/threonine kinase 17b (apoptosis-inducing)                 STK17B, DRAK2         Serine/threonine kinase         Apoptosis                                           STK17B, DRAK2
  Survivin, baculoviral IAP repeat containing 5                            Survivin, BIRC5       Chromosomal pass. complex       Mitosis, cytokinesis, transcription                 BIRC5
  SUZ12, polycomb repressive complex 2 subunit                             SUZ12                 Complex formation               Transcriptional repession, histone methylation      SUZ12
  TACC3, transforming acidic coiled-coil containing protein 3              TACC3, ERIC1          Complex formation               Spindle/microtubule formation, mitosis              TACC3
  Tastin, Trophinin-assisting protein, TROAP                               Tastin, TROAP         Complex formation               Cell adhesion                                       Tastin, TROAP
  TCERG1, transcription elongation regulator 1                             TCERG1, CA150         Transcription factor            Inhibition of transcript elongation                 TCERG1
  TIMELESS, timeless circadian clock                                       TIMELESS, TIM1        Complex formation               Circadian rhythm, DNA repair, replication           TIMELESS
  Thymidine kinase 1                                                       TK1                   Kinase                          DNA synthesis                                       TK1
  Thymopoietin, Lamina-associated polypeptide 2, isoform alpha             TMPO, LAP2            Complex formation               Nuclear structure, post-mitotic nuclear assembly    TMPO, LAP2
  TOP2A, topoisomerase (DNA) II alpha                                      TOP2A                 DNA topoisomerase               Mitosis, meiosis, chromosome segregation            TOP2A
  TPX2, microtubule nucleation factor                                      TPX2                  Complex formation               Mitotic spindle assembly, apoptosis, G2/M trans     TPX2
  TRAIP, TRAF interacting protein, TRIP                                    TRAIP, TRIP           Ubiquitin ligase                Signal transduction, apoptosis, spindle, mitosis    TRAIP, TRIP
  Treslin, TOPBP1 interacting checkpoint and replication regulator         Treslin, SLD3         Complex formation               DNA replication, DNA repair, checkpoint control     TICRR, Treslin
  TTK, Mitotic checkpoint kinase Mps1, TTK protein kinase                  TTK, MPS1             Serine/threonine/tyr. kinase    Spindle formation, mitosis                          TTK, MPS1
  SNRPA, small nuclear ribonucleoprotein polypeptide A                     U1A, SNRPA            Complex formation               U1 snRNA binding, splicing                          SNRPA, U1A
  UACA, Uveal autoantigen with coiled-coil domains and ankyrin repeats     UACA                  Complex formation               Apoptosis                                           UACA
  UBE2C, Ubiquitin-conjugating enzyme E2 C, UbcH10                         UBE2C, UbcH10         Ubiquitin conjug. enzyme        Mitosis                                             UBE2C, UbcH10
  UBE2S, Ubiquitin-conjugating enzyme E2 S                                 UBE2S                 Ubiquitin conjug. enzyme        Exit from mitosis                                   UBE2S
  UBE2T, Ubiquitin-conjugating enzyme E2 T                                 UBE2T, FANCT          Ubiquitin conjug. enzyme        Fanconi anemia, DNA repair, ubiquitination          UBE2T, FANCT
  UDG, uracil DNA glycosylase                                              UDG, UNG              Uracil DNA *N*-glycosylase      DNA repair, base-excision repair                    UNG
  USP1, ubiquitin specific peptidase 1                                     USP1, UBP             Endopeptidase                   De-ubiquitination, neg. regulation DNA repair       USP1
  Wee1-like protein kinase                                                 WEE1                  Serine/threonine kinase         G2/M transition, mitosis                            WEE1
  WD repeat containing antisense to TP53, Telomerase Cajal body pr.        WRAP53, TCAB1         Telomerase component            Telomere maintenance, p53 antisense transcript      WRAP53
  YEATS4, YEATS domain-containing 4                                        YEATS4, GAS41         Complex formation               Transcription, histone acetylation                  YEATS4, GAS41
  ZNF367, zinc-finger protein 367, CDC14B                                  ZNF367                DNA binding                     Transcription                                       ZNF367
  ZRANB3, zinc-finger, RAN-binding domain-containing 3                     ZRANB3, AH2           Helicase and endonuclease       DNA repair, cellular response to DNA damage         ZRANB3, AH2

Genes listed bind DREAM components in their promoters and are downregulated following p53 activation. The list was compiled from meta-analyses reported in several studies.^[@bib17],\ [@bib29],\ [@bib31],\ [@bib66]^ Criteria for inclusion as genes regulated by the p53--p21--DREAM--E2F/CHR (p53--DREAM) pathway are binding of p130, E2F4, LIN9, LIN54, and the lack of binding by p53 as assayed by ChIP together with downregulation of target gene mRNA after activation of p53.^[@bib17],\ [@bib29],\ [@bib31],\ [@bib66]^ An updated compilation of data sets from several genome-wide studies has been published^[@bib65],\ [@bib67]^ and can be consulted to retrieve data on individual genes at [www.targetgenereg.org](http://www.targetgenereg.org).

###### DREAM targets among Fanconi anemia, dyskeratosis congenita, and related DNA repair and telomere maintenance genes

  **Gene name**       **Fanconi**            **DREAM pathway**   **Repressed by p53**
  ------------------- ---------------------- ------------------- ----------------------
  BLM                                        ✓                   ✓
  BRCA1               FANCS                  ✓                   ✓
  BRCA2               FANCD1                 ✓                   ✓
  BRIP1 (BACH1)       FANCJ                  ✓                   ✓
  DCLRE1B (Apollo)                           ✓                    
  DEK                                        ✓                   ✓
  DKC1 (Dyskerin)     Dyskeratosis Congen.   unclear              
  ERCC4 (XPF, RAD1)   FANCQ                  no                   
  FANCA               FANCA                  ✓                   ✓
  FANCB               FANCB                  ✓                   ✓
  FANCC               FANCC                  ✓                    
  FANCD2              FANCD2                 ✓                   ✓
  FANCE               FANCE                  ✓                    
  FANCF               FANCF                  no                   
  FANCG               FANCG                  ✓                    
  FANCI               FANCI                  ✓                   ✓
  FANCL               FANCL                  ✓                    
  FANCM               FANCM                  ✓                   ✓
  FEN1                                       ✓                   ✓
  GAR1                                       unclear             ✓
  PALB2               FANCN                  ✓                   ✓
  RAD51               FANCR                  ✓                   ✓
  RAD51C              FANCO                  unclear             ✓
  RECQL4                                     ✓                   ✓
  RTEL1               Dyskeratosis Congen.   unclear              
  SLX4 (BTBD12)       FANCP                  no                   
  Timeless                                   ✓                   ✓
  TINF2 (TIN2)        Dyskeratosis Congen.   no                   
  UBE2T               FANCT                  ✓                   ✓
  ACD                                        ✓                    
  RIF1                                       ✓                    
  PIF1 (RRM3)                                ✓                    
  RPA2                                       ✓                    
  TRAIP                                      ✓                    
  WRAP53 (TCAB1)                             ✓                    

Abbreviation: DC, dyskeratosis congenita

To assess whether genes related to DNA repair, telomere maintenance^[@bib103],\ [@bib124]^ and Fanconi anemia^[@bib99],\ [@bib100],\ [@bib105]^ are DREAM targets, data on mRNA regulation after p53 activation and binding of DREAM components E2F4, p130, LIN9 and LIN54 were retrieved from a database by Fischer *et al.*^[@bib17]^ An updated data compilation can be accessed at [www.targetgenereg.org](http://www.targetgenereg.org).^[@bib65]^ Jaber *et al.*^[@bib101]^ have recently confirmed that p53 downregulates many of the Fanconi anemia genes by DREAM binding to CDE/CHR sites.
